The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

Participants in the study will receive either Abelacimab or Fragmin® for a period of six months. The study is designed to monitor the recurrence of VTE and any bleeding events during this time. Abelacimab is administered through a method called subcutaneous use, which means it is injected under the skin. Similarly, Fragmin® is also given through subcutaneous injection. The study aims to determine if Abelacimab can prevent VTE recurrence as effectively as Fragmin® and, if successful, to see if it might be even better.

Throughout the study, participants will be closely monitored to track any occurrences of VTE and to ensure their safety. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. However, the evaluation of the study’s outcomes is blinded, meaning that the people assessing the results do not know which treatment the participants received, to ensure unbiased results. The study is expected to continue until 2025, providing valuable information on the effectiveness of Abelacimab in treating VTE in patients with GI or GU cancer.

The purpose of this study is to evaluate the safety and effectiveness of this combination treatment. Participants in the study will receive both medications, with CR6086 taken as a capsule by mouth and Balstilimab given as an infusion into a vein. The study will monitor patients over a period of 24 weeks to see how well the treatment works and to check for any side effects. The goal is to determine if this combination can help control the disease in patients who have already received other treatments.

Throughout the study, doctors will assess the safety of the treatment by observing any side effects and changes in health. They will also measure how well the treatment works by looking at the disease control rate, which includes the number of patients whose cancer shrinks, disappears, or remains stable. This study aims to provide new insights into treating these challenging cancers and potentially offer a new option for patients in the future.

Participants in the study will receive chemotherapy treatments that are adjusted based on their levels of a substance called uracilemia, which is measured before treatment begins. The study will compare different dosing strategies to see which one is most effective in preventing early severe side effects during the first two cycles of treatment. These side effects can include issues with blood cells and the digestive system. The study aims to develop guidelines for safely reducing doses in patients with DPD deficiency.

The trial will involve treatments over a period of several weeks, with regular monitoring to assess how patients respond to the adjusted doses. The study will also look at how effective the treatments are in terms of disease progression and overall survival in patients with stage III and stage IV colorectal cancer. By the end of the study, researchers hope to provide clear recommendations for dosing adjustments in patients with gastrointestinal cancers who have a DPD deficiency.

The purpose of this study is to explore how these treatments affect the immune system’s response to the cancer. Specifically, the study will look at changes in a protein called Interferon gamma (IFN-γ) and the presence of certain immune cells known as cytotoxic T cells in the tumor environment. These immune cells are important because they can help the body fight cancer. The study will involve several stages, starting with initial treatment using Capecitabine and Oxaliplatin, followed by maintenance treatment with Retifanlimab. The study will also include a comparison with a placebo to better understand the effects of the treatment.

Participants in the study will receive the treatment over a period of time, with regular assessments to monitor their response. The study aims to gather information on overall survival, progression-free survival, and the response rate to the treatment. Additionally, it will track any side effects experienced by participants and assess their quality of life during the study. The ultimate goal is to determine if this combination of treatments can provide a beneficial effect for patients with this type of cancer.

The study will test romiplostim (also known as AMG 531) against a placebo. The medication will be given as an injection under the skin. Patients will receive either the study medication or placebo while undergoing their regular oxaliplatin-based chemotherapy. The treatment period will last for 21 days, and the maximum daily dose will be 10 micrograms per kilogram of body weight.

During the study, patients will continue their planned chemotherapy treatments while receiving either romiplostim or placebo. The main focus will be on whether the medication can help patients receive their full chemotherapy doses on schedule without needing to reduce or delay treatment due to low platelet counts. Doctors will monitor platelet levels and check for any side effects throughout the study period.